APA (7th ed.) Citation

S, P., M, G., D, C., U, B., J, L., S, S., . . . T, E. (2012). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational new drugs, 30(1), 341. https://doi.org/10.1007/s10637-010-9493-4

Chicago Style (17th ed.) Citation

S, Pacey, et al. "A Phase II Trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, Tanespimycin) in Patients with Metastatic Melanoma." Investigational New Drugs 30, no. 1 (2012): 341. https://doi.org/10.1007/s10637-010-9493-4.

MLA (9th ed.) Citation

S, Pacey, et al. "A Phase II Trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, Tanespimycin) in Patients with Metastatic Melanoma." Investigational New Drugs, vol. 30, no. 1, 2012, p. 341, https://doi.org/10.1007/s10637-010-9493-4.